Background: the pharmacological treatment and/or maintenance of remission in
inflammatory bowel diseases (IBDs) is currently one of the biggest challenges in the field of …

Aim: The pharmacotherapy of inflammatory bowel disease is difficult and currently available
treatments bring mostly poor and unsatisfactory results. Results: The purpose of this work …

Abstract Background and Aims Pharmacological treatment and/or maintenance of remission
in inflammatory bowel disease [IBD] is currently one of the biggest challenges in the field of …

Pharmacotherapy for inflammatory bowel disease (IBD) is difficult, and some patients do not
respond to currently available treatments. Therefore, the discovery of novel anti-IBD agents …

Opiorphin and sialorphin are two recently discovered endogenous enkephalin‐degrading
enzyme inhibitors. Our aim was to characterize their effect on the mouse ileum motility and to …

Background Inflammatory bowel diseases (IBD) are a group of chronic and recurrent
gastrointestinal disorders that are difficult to control. Recently, a new IBD therapy based on …

The dual inhibitory action of the pain related peptide opiorphin (H-Gln-Arg-Phe-Ser-Arg-OH)
against neutral endopeptidase (NEP) and aminopeptidase N (AP-N) was further …

It is possible that enkephalins are involved in the pain-modulating mechanism in the spinal
cord. Enkephalins, however, are short-lived, being rapidly degraded by various endogenous …

The opioid system plays a crucial role in maintaining gastrointestinal homeostasis.
Endogenous opioid peptide enkephalins have anti-inflammatory effect and participate in the …

Purpose Opioid peptides provide a link between the neuroendocrine and immune systems.
They modify the inflammatory process through their effect on the synthesis and secretion of …